Rxilient

Rxilient is a Singapore-based pharmaceutical company that serves as the Southeast Asian commercialization and manufacturing hub for China Medical System Holdings (CMS). The company focuses on bringing innovative medicines to the ASEAN market across therapeutic areas such as dermatology, ophthalmology, and neurology. Rxilient operates through two main pillars: Rxilient Health, which handles pharmaceutical commercialization, and Rxilient Biotech, which focuses on bioprocessing and manufacturing technologies. By leveraging strategic partnerships with global biotech firms, the company manages a robust pipeline of late-stage and commercial products. Rxilient aims to address unmet medical needs in the region through an integrated model of registration, market access, and local production. The company is also expanding its footprint through a joint venture with Great Bay Bio to establish AI-driven bioprocessing facilities.